These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 37453241)
1. Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study. Reijers SJM; Davies E; Grünhagen DJ; Fiore M; Honore C; Rastrelli M; Vassos N; Podleska LE; Niethard M; Jakob J; Perhavec A; Duarte C; González F; Deroose JP; Stas M; Boecxstaens V; Schrage Y; Snow H; Algarra SM; Said HM; Garcia-Ortega DY; Martin K; Mattsson J; Djafarrian R; Di Lorenzo G; Colombo C; Gronchi A; Matter M; Verhoef C; Olofsson Bagge R; Hohenberger P; Hayes AJ; van Houdt WJ Eur J Cancer; 2023 Sep; 190():112949. PubMed ID: 37453241 [TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study. Huis In 't Veld EA; Grünhagen DJ; Verhoef C; Smith HG; van Akkooi ACJ; Jones R; van Coevorden F; Hayes AJ; van Houdt WJ Eur J Cancer; 2017 Nov; 85():114-121. PubMed ID: 28918185 [TBL] [Abstract][Full Text] [Related]
3. Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities. Boere T; Huis In 't Veld EA; Deroose JP; van Ginhoven TM; Wouters MWJM; Grünhagen DJ; Verhoef C; van Houdt WJ Eur J Surg Oncol; 2020 Jul; 46(7):1315-1319. PubMed ID: 32359920 [TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836 [TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230 [TBL] [Abstract][Full Text] [Related]
6. Impact of hyperthermic isolated limb perfusion on tumour oxygenation in soft tissue sarcoma. Jakob J; von Rege I; Weiss C; Hohenberger P Int J Hyperthermia; 2012; 28(7):591-6. PubMed ID: 22946472 [TBL] [Abstract][Full Text] [Related]
7. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490 [TBL] [Abstract][Full Text] [Related]
8. Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma. Andreou D; Werner M; Pink D; Traub F; Schuler MK; Gosheger G; Jobke B; Reichardt P; Tunn PU Int J Hyperthermia; 2016; 32(2):159-64. PubMed ID: 26670477 [TBL] [Abstract][Full Text] [Related]
9. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039 [TBL] [Abstract][Full Text] [Related]
10. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma. Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373 [TBL] [Abstract][Full Text] [Related]
11. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas. Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370 [TBL] [Abstract][Full Text] [Related]
12. [Limb perfusion in soft tissue sarcomas: twenty years of experience]. Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Pras EB; Suurmeijer A; Hoekstra HJ Ned Tijdschr Geneeskd; 2013; 157(30):A6148. PubMed ID: 23890169 [TBL] [Abstract][Full Text] [Related]
13. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection. Jakob J; Tunn PU; Hayes AJ; Pilz LR; Nowak K; Hohenberger P J Surg Oncol; 2014 Jun; 109(8):786-90. PubMed ID: 24619722 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity. Olofsson R; Bergh P; Berlin O; Engström K; Gunterberg B; Hansson M; Lindnér P; Mattsson J Ann Surg Oncol; 2012 Jun; 19(6):1800-7. PubMed ID: 22219068 [TBL] [Abstract][Full Text] [Related]
15. Lower limb function and quality of life after ILP for soft-tissue sarcoma. Podleska LE; Kaya N; Farzaliyev F; Pöttgen C; Bauer S; Taeger G World J Surg Oncol; 2017 Apr; 15(1):84. PubMed ID: 28403880 [TBL] [Abstract][Full Text] [Related]
16. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Eggermont AM; ten Hagen TL Curr Oncol Rep; 2001 Jul; 3(4):359-67. PubMed ID: 11389822 [TBL] [Abstract][Full Text] [Related]
17. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324 [TBL] [Abstract][Full Text] [Related]
18. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients? Deroose JP; Burger JW; van Geel AN; den Bakker MA; de Jong JS; Eggermont AM; Verhoef C Ann Surg Oncol; 2011 Feb; 18(2):321-7. PubMed ID: 21049306 [TBL] [Abstract][Full Text] [Related]
19. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma. Jakob J; Hohenberger P Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621 [TBL] [Abstract][Full Text] [Related]
20. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]